Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V, Testoni N, Spadano A, Terragna C, Pescosta N, Marzocchi G, Cellini C, Galieni P, Ronconi S, Gobbi M, Catalano L, Lazzaro A, De Sabbata G, Cangialosi C, Ciambelli F, Musto P, Elice F, Cavo M; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network). Tacchetti P, et al. Among authors: barbato s. Lancet Haematol. 2020 Dec;7(12):e861-e873. doi: 10.1016/S2352-3026(20)30323-9. Lancet Haematol. 2020. PMID: 33242443 Clinical Trial.
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bodéré F. Zamagni E, et al. Among authors: barbato s. J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5. J Clin Oncol. 2021. PMID: 33151787
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Rizzello I, Cavo M, Dozza L, Rivolti E, Petrucci MT, De Stefano V, Antonioli E, Tosi P, D'Agostino M, Morè S, Gozzetti A, Cea M, Barbato S, Tacchetti P, Pantani L, Mancuso K, Rocchi S, De Cicco G, Fusco A, Zamagni E. Rizzello I, et al. Among authors: barbato s. Leuk Lymphoma. 2021 Aug;62(8):1897-1906. doi: 10.1080/10428194.2021.1897805. Epub 2021 Mar 18. Leuk Lymphoma. 2021. PMID: 33733993
How I treat high-risk multiple myeloma.
Zamagni E, Barbato S, Cavo M. Zamagni E, et al. Among authors: barbato s. Blood. 2022 May 12;139(19):2889-2903. doi: 10.1182/blood.2020008733. Blood. 2022. PMID: 34727187 Free article. Review.
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Vigliotta I, Rizzello I, Rocchi S, Armuzzi S, Testoni N, Marzocchi G, Martinelli G, Cavo M, Terragna C. Martello M, et al. Among authors: barbato s. Blood Cancer J. 2022 Jan 26;12(1):15. doi: 10.1038/s41408-022-00610-y. Blood Cancer J. 2022. PMID: 35082295 Free PMC article.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Tacchetti P, Rocchi S, Zamagni E, Barbato S, Rizzello I, De Cicco G, Pantani L, Mancuso K, Fusco A, Dozza L, Ursi M, Favero E, Terragna C, Testoni N, Cavo M. Tacchetti P, et al. Among authors: barbato s. Am J Hematol. 2022 Dec;97(12):1607-1615. doi: 10.1002/ajh.26747. Epub 2022 Oct 18. Am J Hematol. 2022. PMID: 36198076 Free PMC article.
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
Mancuso K, Zamagni E, Solli V, Gabrielli L, Leone M, Pantani L, Rocchi S, Rizzello I, Tacchetti P, Ghibellini S, Favero E, Ursi M, Talarico M, Barbato S, Kanapari A, Bigi F, Puppi M, Terragna C, Borsi E, Martello M, Poletti A, Scatà A, Nepoti G, Ruffini B, Lazzarotto T, Cavo M. Mancuso K, et al. Among authors: barbato s. Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023. Front Oncol. 2023. PMID: 37305577 Free PMC article.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C. Zamagni E, et al. Among authors: barbato s. EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396807 Free PMC article.
43 results